Richard Dalby, PhD, BPharm, is a Professor in the Department of Pharmaceutical Sciences at the University of Maryland School of Pharmacy

Richard Dalby, PhD

Richard Dalby, PhD, BPharm
Professor, Department of Pharmaceutical Sciences

University of Maryland School of Pharmacy
20 N Pine Street, N629
Baltimore, MD 21201


Postdoctoral, PhD, MS – Not currently recruiting


  • PhD, Pharmaceutical Sciences, University of Kentucky
  • BPharm, University of Notitngham

Research Interests

The aerosol lab has extensive experience in the formulation & evaluation of pressurized metered dose inhaler, dry powder inhaler, nebulizer & nasal spray platforms, and development & evaluation of novel & existing test methods with regulatory implications for orally inhaled and nasal pharmaceutical products. We have conducted projects that are invitro-only and those which necessitated use of human (inc. pediatric) subjects to assess the interaction between inhalation devices and patients. Since 2016 we have leveraged experience with pharmaceutical aerosols into FDA-funded studies to elucidate the potential hazards of electronic cigarettes, including partnering with other labs to determine harmful and potentially harmful constituents of the emitted vapor and aerosol, and investigating the potential of e-cigarettes to defeat the abuse deterrent design of extended-release solid oral opiate dosage forms. Recently we have worked on measures to protect healthcare professionals from exposure to aerosols potentially containing SARS-CoV-2.

About Dr. Dalby

Dr. Dalby received his BPharm from the University of Nottingham and his PhD from the University of Kentucky. In addition to serving as a professor in the Department of Pharmaceutical Sciences (PSC), he is a fellow of the American Association of Pharmaceutical Scientists (AAPS) and a member of the Royal Pharmaceutical Society of Great Britain. His research interests include the formulation and evaluation of pressurized metered dose inhaler, dry powder, nebulizer, and nasal spray products; the development and evaluation of existing and proposed test methods for inhalation products; laboratory testing and patient evaluation of novel pulmonary and nasal delivery devices; and the design of patient education aids. He has more than 25 years experience as an independent consultant working with both national and international companies, and has served as an expert witness and advisor for pharmaceutical companies engaged in intellectual property and other disputes associated with inhaled and nasal medications and devices.

Current Projects

  1. Collection of aerosol emitted from various types of electronic cigarettes for quantification of organic and metallic constituents.
  2. Investigation of arrayed electronic sensors to detect the constituents of aerosols generated by electronic cigarettes.

Publications since 2018 (of 56 peer reviewed publications)

  1. Use Of An Extraoral Suction Unit To Minimize Aerosol Spatter During A Simulated Dental Procedure. Sydnee Chavis, Stella Hines, Donita Dyalram, Nicholas Cole Wilken and Richard N. Dalby. Journal of the American Dental Association. 152(2): 157–165. February 2021. DOI: 10.1016/j.adaj.2020.10.010.
  2. Cigalike Electronic Nicotine Delivery Systems E-liquids Contain Variable Levels Of Metals; Heather M. Neu, Angela Lee, Joel E.P. Brandis, Vyomesh Patel, Abraham Schneider, Maureen A. Kane, Richard N. Dalby and Sarah L.J. Michel. Scientific Reports. Vol. 10, Article number: 11907. July 2020. DOI: 10.1038/s41598-020-67789-7.
  3. Clinical Implications of the Tiotropium/Olodaterol Inhaler for Patients with Chronic Obstructive Pulmonary Disease; Gary T. Ferguson and Richard N. Dalby. Journal of Postgraduate Medicine. Vol. 130, Issue 6, Pages 515-522, July 2018. DOI: 10.1080/00325481.2018.1481713.

Download Dr. Dalby’s CV